Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study
dc.contributor.author | Urba, Susan G. | en_US |
dc.contributor.author | Chansky, Kari | en_US |
dc.contributor.author | van Veldhuizen, Peter J. | en_US |
dc.contributor.author | Pluenneke, Robert E. | en_US |
dc.contributor.author | Benedetti, Jacqueline K. | en_US |
dc.contributor.author | Macdonald, John S. | en_US |
dc.contributor.author | Abbruzzese, James L. | en_US |
dc.date.accessioned | 2006-09-11T15:50:17Z | |
dc.date.available | 2006-09-11T15:50:17Z | |
dc.date.issued | 2004-01 | en_US |
dc.identifier.citation | Urba, Susan G.; Chansky, Kari; vanVeldhuizen, Peter J.; Pluenneke, Robert E.; Benedetti, Jacqueline K.; Macdonald, John S.; Abbruzzese, James L.; (2004). "Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study." Investigational New Drugs 22(1): 91-97. <http://hdl.handle.net/2027.42/45241> | en_US |
dc.identifier.issn | 0167-6997 | en_US |
dc.identifier.issn | 1573-0646 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45241 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14707499&dopt=citation | en_US |
dc.description.abstract | Purpose : Experimental data, both in vivo and in vitro , suggest that the combination of gemcitabine and cisplatin acts synergistically. Within the Southwest Oncology Group, we designed a Phase II trial to test this chemotherapy combination for patients with esophageal cancer. Experimental design : Patients with metastatic or recurrent esophageal cancer were treated with gemcitabine 1000 mg/m 2 on days 1, 8, and 15, and cisplatin 100 mg/m 2 on day 15. Cycles were repeated every 28 days. The statistical endpoint was overall survival. Results : Sixty-four eligible patients were accrued from 37 institutions. Twenty-six percent of patients had prior chemotherapy. The treatment was generally well-tolerated, with the most common toxicity being neutropenia in 31% of patients. All 64 patients have died. Survival at 3 months was 81%, and at 1 year was 20%. Median survival was 7.3 months. Conclusions : This regimen is tolerable palliative option for patients with metastatic esophageal cancer. | en_US |
dc.format.extent | 82314 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers; Springer Science+Business Media | en_US |
dc.subject.other | Medicine & Public Health | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Oncology | en_US |
dc.subject.other | Esophageal Cancer | en_US |
dc.subject.other | Chemotherapy | en_US |
dc.subject.other | Gemcitabine | en_US |
dc.subject.other | Cisplatin | en_US |
dc.title | Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Radiology | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, MI, U.S.A. | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, WA, U.S.A | en_US |
dc.contributor.affiliationother | University of Kansas Medical Center, Kansas City, MO | en_US |
dc.contributor.affiliationother | Kansas City Community Clinical Oncology Program, Kansas City, MO | en_US |
dc.contributor.affiliationother | Southwest Oncology Group Statistical Center, Seattle, WA, U.S.A | en_US |
dc.contributor.affiliationother | St Vincent's Comprehensive Cancer Center, New York, NY, U.S.A | en_US |
dc.contributor.affiliationother | MD Anderson Cancer Center, Houston, TX, U.S.A | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 14707499 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45241/1/10637_2004_Article_5151120.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/B:DRUG.0000006179.20974.af | en_US |
dc.identifier.source | Investigational New Drugs | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.